American Journal of Cardiology
Volume 102, Issue 4 , Pages 386-390 , 15 August 2008

Safety of Diagnostic Coronary Angiography During Uninterrupted Therapeutic Warfarin Treatment

  • Antti-Pekka Annala, MD

      Affiliations

    • Department of Cardiology, Satakunta Central Hospital, Pori, Finland
    • ,
  • Pasi P. Karjalainen, MD, PhD

      Affiliations

    • Department of Cardiology, Satakunta Central Hospital, Pori, Finland
    • ,
  • Pekka Porela, MD, PhD

      Affiliations

    • Department of Medicine, Turku University Hospital, Turku, Finland
    • ,
  • Kai Nyman, MD

      Affiliations

    • Department of Medicine, Jyväskylä Central Hospital, Jyväskylä, Finland.
    • ,
  • Antti Ylitalo, MD, PhD

      Affiliations

    • Department of Cardiology, Satakunta Central Hospital, Pori, Finland
    • ,
  • K.E. Juhani Airaksinen, MD, PhD

      Affiliations

    • Department of Medicine, Turku University Hospital, Turku, Finland
    • Corresponding Author InformationCorresponding author: Tel: 358-2-313-1005; fax: 358-2-313-2030.

Received 7 February 2008 ,Revised 2 April 2008 ,Accepted 2 April 2008.

References 

  1. Popma JJ, Bittl JA. Coronary angiography and intravascular ultrasonography. In:  Braunwald E,  Zipes DP,  Libby P editor. Heart Disease: Textbook of Cardiovascular Medicine. 6th Ed.. Philadelphia: WB Saunders; 2001;p. 387–421
  2. Grossman W. Historical perspective and present practice of cardiac catheterisation. In:  Baim D editors. Grossman's Cardiac Catheterization, angiography and intervention. 6th Ed.. Philadelphia: Lippincott Williams & Wilkins; 2000;p. 1–8
  3. Ansell J, Hirch J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(suppl):201S–233S
  4. Kearon D, Hirch J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506–1511
  5. Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol. 1999;84:478–480
  6. Lev-Ran O, Kramer A, Gurevitch J, Shapira I, Mohr R. Low-molecular-weight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg. 2000;69:264–265
  7. Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, et al Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation. 2007;116:2531–2534
  8. Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen M-A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28:726–732
  9. Korkeila P, Saraste M, Nyman K, Koistinen J, Lund J, Airaksinen KEJ. Transesophageal echocardiography in the diagnosis of thrombosis associated with permanent transvenous pacemaker electrodes. Pacing Clin Electrophysiol. 2006;29:1245–1250
  10. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001;285:2864–2870
  11. Helft G, Gilard M, Le Feuvre C, Zaman AG. Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation. Nat Clin Pract Cardiovasc Med. 2006;3:673–680
  12. Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;(168):63–69
  13. MacDonald LA, Meyers S, Bennett CL, Fintel D, Grosshans N, Syegco R, et al. Post-cardiac catheterization access site complications and low-molecular-weight heparin following cardiac catheterization. J Invasive Cardiol. 2003;15:60–62
  14. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(suppl):8S–21S
  15. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, et al Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the superior yield of the new strategy of enoxaparin, revascularization and glycoprotein IIb/IIIa inhibitors (SYNERGY) trial. Am Heart J. 2006;152:1042–1050
  16. Larson BJG, Zumberg MS, Kitchens CS. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk. Chest. 2005;127:922–927
  17. Hildick-Smith DJR, Walsh JT, Lowe MD, Petch MC. Coronary angiography in the fully anticoagulated patient: The transradial route is successful and safe. Catheter Cardiovasc Interv. 2003;58:8–10
  18. Jessup DB, Coletti AT, Muhlestein JB, Barry WH, Shean FC, Whisenant BK. Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy. Catheter Cardiovasc Interv. 2003;60:180–184
  19. El-Jack SS, Ruygrok PN, Webster MW, Stewart JT, Bass NM, Armstrong GP, et al. Effectiveness of manual pressure hemostasis following transfemoral coronary angiography in patients on therapeutic warfarin anticoagulation. Am J Cardiol. 2006;97:485–488

 This study was supported by grants from the Finnish Foundation for Cardiovascular Research, Helsinki, Finland.

PII: S0002-9149(08)00645-0

doi: 10.1016/j.amjcard.2008.04.003

American Journal of Cardiology
Volume 102, Issue 4 , Pages 386-390 , 15 August 2008

Article Tools